Cumulative level test: Appraising and applying skin evidence: measurement, trials and formulation decisions

Check understanding, separately from reading

12 questions · 80% to pass · no timer. This longer test revisits both units in the level. These authored questions assess recognition and application of the taught distinctions, not professional qualification. You may review the lessons and retry. Repeat attempts reuse the question bank; a remembered answer is not proof of transfer to a new situation.

Saving a lesson records reading only. Previous lesson completions have not been converted into passing scores. You can continue reading without a pass; the assessment remains unpassed.

Question 1

Cumulative application. A brand presents a barrier claim as follows: trans-epidermal water loss fell 22 per cent in a four-week study of 28 participants using the product, measured on the forearm with an open-chamber device, and the same product is recommended on its website for use around the eyes. A learner with reactive cheeks and a diagnosed corneal condition asks whether to buy it. Build the appraisal in the order this level teaches, naming the site, the instrument, the design and the boundary. State what the 22 per cent does and does not establish, and state what you would do about the eye-area recommendation.First, the site: forearm evidence is evidence about the forearm, and the eyelid is the thinnest skin on the body at 0.55 mm with easier allergen penetration, so the eye-area recommendation is unsupported by the study. Second, the instrument: a 22 per cent fall in a water-loss rate needs the site's reliability and the method's measurement error, and forearm TEWL reliability has been reported anywhere from 0.74 to 0.4. Third, the design: a single-arm four-week study cannot separate product effect from regression to the mean, seasonal humidity change or altered routine. Fourth, the boundary: anything at the lid margin, lashes or ocular surface with a diagnosed corneal condition belongs to an eye-care clinician, so the eye recommendation is a clinical question, while the cheek question continues as a monitored trial with a stop rule.The study is adequate for both uses because it measured a physiologically relevant endpoint at a relevant duration in 28 participants, and the eye-area recommendation follows from the product being the same formula; the only remaining caveat is that 28 participants is a small sample.

Question 2

Cumulative application. Two colleagues present evidence for the same barrier cream. Colleague one cites a study in which capacitance readings rose from 42 to 51 arbitrary units after eight weeks in a single treated group. Colleague two cites a regional measurement study reporting that TEWL reliability ranges from 0.74 to 0.4 across sites while capacitance reliability was above 0.75 everywhere. Colleague one concludes the cream works and colleague two says the number cannot be interpreted. Using instrument and design reasoning, adjudicate, and include the arithmetic that converts the change into units and compares it with an illustrative measurement error.Colleague one is correct because the change exceeds the measurement error and the reported reliability was good, so the cream works; colleague two is confusing instrument error with study design, which are independent topics.Both are partly right and the reasoning is separable. The arithmetic is a change of 9 units on a baseline of 42, which is 21 per cent, so the percentage is reported correctly. The design is a single-arm before-and-after comparison, which cannot exclude regression to the mean, season, humidity or changed behaviour. The measurement point is that capacitance is the more reliable of the two methods in the cited study, with reliability above 0.75 at every site, but reliability below 1 still implies error: if the between-person standard deviation were 12 units, a reliability of 0.75 gives a measurement error of 12 multiplied by the square root of 0.25, which is 6 units. A 9-unit change is larger than a 6-unit error, so it is plausible and modest rather than established, and a between-group comparison of the same size would be substantially stronger evidence.

Question 3

Cumulative application. A cosmetic trial reports that 60 participants were randomised to active or vehicle, that 48 completed, and that the active group improved significantly in the per-protocol analysis of completers. The abstract says the treatment was proven effective. Identify the specific reporting and analysis problems, state what the intention-to-treat analysis would require, and name the two checklist items a reader should look for that this summary omits.The problems are analysis population and reporting. Analysing only the 48 completers breaks the comparison randomisation created, because non-completion is related to tolerability and motivation; the CONSORT authors replaced the phrase intention to treat with an explicit request for information about retaining participants in their originally assigned groups precisely because that term is misused. An intention-to-treat analysis requires outcomes for every randomised participant, analysed in the assigned group, with any missing data handled by a stated method. The two omitted checklist items are how the allocation sequence was concealed from recruiters and who was blinded to what, including whether the outcome assessor was blinded. Proven effective is also an overstatement of a result measured on a self-reported or investigator-rated scale in a single trial.The main problem is the small sample and the 20 per cent loss to follow-up; once the trial is large enough, restricting analysis to completers is a legitimate way to improve data quality, and the abstract wording is a minor style issue.

Question 4

Cumulative application. A 40-participant split-face trial finds no significant difference between the treated and control sides at twelve weeks, and the brand argues that the null result nevertheless shows the design was rigorous. A sceptical reader argues the null result proves the product does not work. Using the design logic from this level, state the correct interpretation and explain what further information would change the conclusion.Because the trial was randomised, blinded and split-face, the null result is definitive: a rigorous design that finds nothing means the product has no effect, and the sceptical reader is correct.Neither argument is sound. A split-face design is efficient because it removes between-person variance, which raises the information per participant, but it assumes the two sides are independent: if product migrates across the midline or if treatment produces a shared systemic effect, the observed difference is diluted toward zero. A null split-face result can therefore reflect either no effect or a design that suppressed the effect, and a design cannot be validated by its own null result. What would change the conclusion is a reported effect size with its precision, an appropriately blinded assessor, cross-midline migration accounted for, and a parallel-group or independent-site comparison, since a null result in a design capable of detecting the expected difference would be substantially more informative.

Question 5

Cumulative application. A learner finds three sources on one question: a manufacturer summary reporting a 30 per cent wrinkle improvement, a network meta-analysis ranking retinoids highest among topical agents with a stated safety caveat, and a systematic review noting spin in abstracts of dermatology meta-analyses. Explain how to weigh the three, what the 30 per cent needs before it can be compared with the network meta-analysis, and what the spin study changes about how the learner should read the other two.Weigh them by question and method, not by number. The manufacturer summary is promotional material, so it is labelled as such and it reports a relative change whose scale, comparator, duration and precision must be recovered before any comparison: 30 per cent of a nine-point baseline of 5.0 is 1.6 points, which is meaningful only if it came from a randomised blinded comparison that exceeded the error of the rating scale. The network meta-analysis answers a different question, namely the comparative ranking of topical interventions across 23 randomised trials and 3,905 participants, and it carries its own limitation, since ranking through indirect comparisons assumes that vehicles, concentrations, populations and durations are similar enough to combine. The spin study changes reading habits rather than conclusions: it shows that abstracts can misrepresent results, so the learner reads the results and limitations sections for the primary outcome rather than trusting the abstract, and treats favourable framing as a reason to check, not as evidence.The network meta-analysis is the strongest source and should simply be preferred, and since it is a synthesis rather than a manufacturer document, the spin finding applies only to industry-funded material and can be set aside.

Question 6

Cumulative application. A learner with a diagnosed corneal condition and impaired vision wants to try a new under-eye cream marketed as ophthalmologist tested, and asks whether she should also resume applying eyeliner at the inner lash line because a video showed it makes eyes look larger. Using the periorbital evidence, answer both parts, name the mechanism by which the eyeliner change matters, and state the stop rule that should accompany any decision.A product marked ophthalmologist tested has been assessed for the eye area, so it is suitable despite the corneal condition, and eyeliner at the inner lash line is a stylistic choice because the tear film renews continuously and removes any transferred product.Treat the two parts separately and route the second to a clinician. An eye cream applied to the outer periorbital skin is a cosmetic question at the thinnest, most permeable skin on the body, and the claim that it was tested does not address a managed corneal condition, so the product and the question go to the eye-care clinician who can examine the cornea and tear film. Eyeliner at the inner lash line is a different question, because migration across the lid margin has been described and inner-line application is associated with greater tear film contamination and ocular discomfort than application on the outer periocular skin, with makeup removers also shown to increase tear film evaporation. The stop rule is that new eye pain, light sensitivity, discharge, persistent redness or any change in vision means seeking care promptly rather than adjusting a routine.

Question 7

Cumulative application. A dermatologist recommends an occlusive ointment for lichenified skin on a shin. The learner dislikes it and asks whether the lighter lotion she prefers delivers the same active, since the percentage on the label is identical. Explain what the vehicle changes, give the site-based reasoning, and include the arithmetic that converts measured delivery into a share of the applied dose.The percentage is the same and the delivered amount is not. A vehicle changes how available the active is, how much water the stratum corneum holds while the base sits on it, and how long contact lasts, and the vehicle review groups thickened and lichenified skin with the situations where more occlusive bases are preferred. The arithmetic shows the scale: in a 56-compound penetration study using a finite dose of 10 microlitres per square centimetre, delivery ranged from 0.03 to 72.61 micrograms per square centimetre, a factor of about 2,420 between compounds, and if that dose is approximately 10,000 micrograms per square centimetre then the most permeable compound delivered about 0.73 per cent of what was applied while the least delivered about 0.0003 per cent. Consistency of use is the other half of the equation, so the reasonable plan is an occlusive base at night on the thickened area and a preferred lighter product by day, with tolerability treated as part of delivery rather than as vanity.The same percentage means the same delivered dose, so the preference for the lotion is legitimate and the dermatologist's recommendation is a matter of texture and habit rather than of formulation science.

Question 8

Cumulative application. A learner with a history of a rash from a scented body lotion wants to eliminate risk by choosing fragrance-free and paraben-free products, and she wants to know whether that plan is sound. Evaluate the plan using hazard and risk reasoning, the preservative patch-test frequencies, the fragrance labelling rules and the contamination argument.The plan is sound as written, because removing fragrances and parabens removes the two most common causes of cosmetic contact dermatitis, and preservative-free products avoid both allergy and contamination risk.The plan is partially reasonable and not sufficient. Avoiding a substance that caused a reaction is sensible, but identifying what caused it is a clinical question answerable by patch testing rather than by label avoidance, because fragrances are among the allergen groups reported for periorbital and general contact dermatitis. The preservative data show why a free-from strategy can backfire: in a 50,799-patient series, 22.3 per cent reacted to at least one preservative, methylisothiazolinone reacted in 12.2 per cent and paraben mix in 1 per cent, roughly a twelvefold difference, so removing a paraben says nothing about what replaced it. Fragrance disclosure also limits the plan, since United States rules permit fragrance and flavour ingredients to be listed simply as fragrance to protect trade secrets, so a scented product's sensitiser may be unidentifiable from the label. Finally, a preservative-free, water-containing product carries a contamination argument of its own, since preservation is a consumer-protection function verified by challenge testing and good manufacturing practice, and jar formats opened with fingers add exposure. The sound plan is patch testing, a written avoidance list based on results, and a preference for well-preserved, appropriately packaged, low-fragrance products.

Question 9

Cumulative application. A brand's serum claims to deliver a growth-factor complex that rebuilds collagen, and the cited study measured wrinkle depth at eight weeks in 45 participants with no control group, reporting a 12 per cent relative improvement. A second brand sells a much cheaper matrikine peptide serum and cites a review of products with evidence of skin rejuvenation. Compare the two claims on outcome evidence and mechanism, include the arithmetic, and state what would move either claim into the likely category.Both claims need separating into measured outcome and stated mechanism. The arithmetic first: 12 per cent of a baseline of 5.0 on a nine-point scale is 0.6 points, which is smaller than typical inter-rater variation on wrinkle severity scales, and with no control group it is also compatible with regression to the mean and behaviour change. The mechanism claim about rebuilding collagen is unsupported by that study, and the review literature notes that growth-factor proteins are poorly penetrating while matrikine and matrikine-like peptides have better penetration because they are much smaller, which if anything favours the cheaper product's plausibility while still not measuring an outcome. What would move either claim to likely is a randomised comparison with a relevant blinded endpoint, a stated duration, an effect exceeding the error of the measurement instrument, and disclosure of funding and interests, since the substantiation standard requires competent and reliable scientific evidence for health-related claims.The growth-factor serum is the stronger product because growth factors directly signal collagen synthesis, whereas the matrikine peptide only mimics that activity, so the mechanism difference settles the comparison.

Question 10

Cumulative application. A learner wants to buy a microbiome-balancing serum, has 300 dollars a year to spend on skincare, and also reports recurrent stinging on the cheeks and a persistent dry patch on a shin that has not healed in three months. Build the priorities she should follow, including which question is clinical, which interventions have the best evidence behind them, and how to reason about the microbiome claim.Buy the microbiome serum first because it addresses the skin ecosystem underlying both problems, then use the remaining budget on a moisturiser, and treat the dry patch as dryness to be solved with the same routine.Sort by evidence strength and by clinical urgency. The dry patch that has not healed over three months is a clinical matter and takes priority over any purchase, because a non-healing or changing lesion is a reason to seek assessment rather than to treat cosmetically. The stinging is a tolerability and possibly contact-allergy question, managed by simplifying to a gentle cleanser, a plain emollient and photoprotection, and by seeking patch testing if it persists. The microbiome claim should be filed as preliminary rather than dismissed, since reviews state that the microbiome maintains barrier and homeostasis while evidence for microbiome-targeted cosmetics remains preliminary and microbiome-friendly describes a design intention. With a 300-dollar annual budget, the arithmetic favours the boring interventions: a ceramide or plain emollient moisturiser used generously on the cheeks and the shin will cost a fraction of a premium serum, leaving budget for a broad-spectrum sunscreen, which is the intervention with the strongest evidence in the course.

Question 11

Cumulative application. A learner is building her first dossier and asks you to check the seven sections. She has a question, nine sources including four manufacturer brochures, a summary paragraph, a conclusion that the product is worth trying, and a note saying she will stop if it irritates her skin. Diagnose what is missing, state the criteria that should determine her certainty label, and explain the two kinds of stop rule the dossier needs.Four sections are missing or too vague. The question needs explicit population, intervention, comparison and outcome slots, because without a named comparison the dossier becomes a purchase justification. The sources need rung labels and an appraisal note each, with manufacturer material marked as promotional even when it carries data, and the appraisal template should follow the Cochrane bias domains for trials and a review-level tool for syntheses. The certainty label must be one of likely, uncertain or insufficient chosen by written criteria: likely requires at least one randomised comparison with a relevant outcome and no serious risk-of-bias problem, uncertain means randomised evidence exists but is small, short, inconsistent or indirect, and insufficient means no randomised comparison addresses the endpoint. The cost line is absent and should be computed per year at a stated application volume so products of different sizes can be compared. The stop rule must have two kinds, a tolerance stop for irritation, stinging or new scaling that persists, and a clinical stop for symptoms that belong to a clinician, with anything at the lid margin, lashes or ocular surface routed to an eye-care clinician. A review date and a statement of what would change the decision are also required, since a conclusion that the product is worth trying is a decision with no criteria attached.The dossier is essentially complete: nine sources exceed the minimum, the conclusion follows from the evidence gathered, and a single irritation-based stop rule covers the necessary safety element, so the remaining work is cosmetic tidying.

Question 12

Cumulative synthesis. A learner presents a plan that uses four products, including a peptide serum, a microbiome serum, an acid exfoliant and an eye area cream applied to the lid margin, justifies each with a mechanism, and reports that she cannot afford a sunscreen. Rebuild the plan using the evidence hierarchy from this level, name the arithmetic that shows where the money should go, and state precisely how the eye-area item changes and why.Keep the four products because each is supported by a mechanism, add sunscreen when the budget allows, and keep the eye cream as formulated since it is designed for the eye area and the label directions specify the intended site.Rebuild from evidence strength downward. The strongest evidence in this level supports photoprotection, moisturising with an appropriate vehicle, a gentle cleanser, and a single well-evidenced active trialled one at a time, so the first structural change is to move sunscreen into the plan and treat it as the least negotiable item, since it protects against the process that the other products claim to address. The two mechanism-justified serums should be filed as uncertain or insufficient until a randomised comparison with a relevant blinded endpoint exists, with the peptide review noting limited stratum corneum permeability for a hydrophilic molecule and the microbiome review noting that evidence for microbiome-targeted cosmetics remains preliminary. The exfoliant is a tolerability risk layered on top of stinging, so it goes last or not at all. The arithmetic shows why this ordering frees budget: a product costing 48 dollars for 30 millilitres at 0.5 millilitres twice daily costs 1.60 dollars per millilitre and about 584 dollars a year, while a 50-millilitre product at 22 dollars costs 0.44 dollars per millilitre and about 161 dollars a year, a difference of about 423 dollars that can fund sunscreen and a larger emollient. The eye-area item changes by site and by authority: the lid margin is adjacent to the tear film, migration across the margin has been described, inner-line application is associated with greater tear film contamination and discomfort than outer periocular application, and with a diagnosed corneal condition that area is managed by an eye-care clinician, so the product is either repositioned to the outer periorbital skin under clinical advice or removed from the plan, never applied at the margin.

Continuing does not mark this assessment passed.

Progress stays in this browser, on this device, not an account or cloud backup. Clearing browser data removes it. Visits never count as study. Previous untimed legacy completions are not invented as study days.